Work

Trabectedin, a drug acting on both cancer cells and the tumour microenvironment

Year: 2014

Type: review

Abstract: Trabectedin is the first marine-derived anti-neoplastic drug approved for the treatment of advanced soft tissue sarcoma and, in combination with pegylated liposomal doxorubicin, for the treatment of patients with relapsed platinum-sensitive ovarian cancer. From the beginning of its development, trabectedin showed some peculiar properties that clearly distinguished it from other anti-cancer drugs. In this mini-review, we will outline the current state of knowledge regarding the mode of action of trabectedin, which appears to represent a new class of anti-neoplastic drugs acting both on cancer cells and on the tumour microenvironment.

Source: British Journal of Cancer

DOI: 10.1038/bjc.2014.149

Authors: M D’Incalci, N Badri, C M Galmarini, P Allavena

Institutions: Mario Negri Institute for Pharmacological Research, PharmaMar (Spain)

Language: English

Topic: Cancer therapeutics and mechanisms

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $5,190